Niklas Zojer
Overview
Explore the profile of Niklas Zojer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
893
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ludwig H, Melchardt T, Schweitzer I, Sormann S, Schreder M, Andel J, et al.
EJHaem
. 2024 Jun;
5(3):494-504.
PMID: 38895059
Understanding the impact of induction and maintenance therapy on patients' quality of life (QoL) is important for treatment selection. This study aims to compare patient-reported QoL between patients treated with...
2.
Ludwig H, Melchardt T, Sormann S, Schreder M, Andel J, Hartmann B, et al.
Am J Hematol
. 2024 Mar;
99(5):1008-1011.
PMID: 38425185
Randomized comparison between KTd and KRd induction followed by second randomization to carfilzomib in transplant-ineligable patients with newly diagnosed multiple myeloma.
3.
Pfeiffer C, Grandits A, Asnagli H, Schneller A, Huber J, Zojer N, et al.
Leukemia
. 2023 Oct;
38(1):181-192.
PMID: 37898670
Targeting nucleotide biosynthesis is a proven strategy for the treatment of cancer but is limited by toxicity, reflecting the fundamental nucleotide requirement of dividing cells. The rate limiting step in...
4.
Ludwig H, Kainz S, Schreder M, Zojer N, Hinke A
EClinicalMedicine
. 2023 Mar;
58:101910.
PMID: 36969337
Background: Biomarker-defined patients with smoldering multiple myeloma (SMM) were included in the diagnostic category of multiple myeloma (MM) by the International Myeloma Working Group (IMWG) in 2014. This includes ≥60%...
5.
Niederwieser D, Lang T, Krahl R, Heinicke T, Maschmeyer G, Al-Ali H, et al.
Ann Hematol
. 2023 Jan;
102(3):547-561.
PMID: 36695874
A randomized inter-group trial comparing more intensive treatment strategies to a common standard arm 3 + 7 (CSA) was conducted in patients with non-M3 AML. Untreated patients ≥ 60 years...
6.
Mayr M, Zojer N, Mirzaei S, Chott A
Pathologie (Heidelb)
. 2022 Aug;
43(6):449-453.
PMID: 35925312
We report on a 47-year-old patient suffering from bilateral gonalgia, weight loss and night sweats without fever of several months' duration. Diagnostic work-up for infectious and autoimmune diseases showed no...
7.
Ludwig H, Hausmann B, Schreder M, Ponisch W, Zojer N, Knop S, et al.
EJHaem
. 2022 Jul;
2(1):99-103.
PMID: 35846090
Alterations in the human microbiome have been linked to several malignant diseases. Here, we investigated the oral microbiome of 79 patients with relapsed/refractory multiple myeloma (MM) treated with ixazomib-thalidomide-dexamethasone. Increased...
8.
Ludwig H, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, et al.
Lancet Haematol
. 2021 Nov;
8(12):e934-e946.
PMID: 34756169
Patients with multiple myeloma frequently present with substantial immune impairment and an increased risk for infections and infection-related mortality. The risk for infection with SARS-CoV-2 virus and resulting mortality is...
9.
Kornauth C, Pemovska T, Vladimer G, Bayer G, Bergmann M, Eder S, et al.
Cancer Discov
. 2021 Oct;
12(2):372-387.
PMID: 34635570
Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment...
10.